相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Kevin Litchfield et al.
CELL (2021)
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Min Zhang et al.
NATURE COMMUNICATIONS (2021)
High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets
Xiaoshan M. Shao et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review
Vasiliki Panou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm
Caroline Robert et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Michele Carbone et al.
CANCER DISCOVERY (2020)
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
Anna K Nowak et al.
LANCET ONCOLOGY (2020)
Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma
Angela Bononi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
Valsamo Anagnostou et al.
CELL REPORTS MEDICINE (2020)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Robert M. Samstein et al.
NATURE CANCER (2020)
Tumour predisposition and cancer syndromes as models to study gene-environment interactions
Michele Carbone et al.
NATURE REVIEWS CANCER (2020)
Integrated Informatics Analysis of Cancer-Related Variants
Kymberleigh A. Pagel et al.
JCO CLINICAL CANCER INFORMATICS (2020)
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
Valsamo Anagnostou et al.
NATURE CANCER (2020)
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Aaron S. Mansfield et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Neoantigen-directed immune escape in lung cancer evolution
Rachel Rosenthal et al.
NATURE (2019)
Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
Raffit Hassan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Giorgio V. Scagliotti et al.
LANCET RESPIRATORY MEDICINE (2019)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2019)
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
Anne S. Tsao et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Kroopa Joshi et al.
NATURE MEDICINE (2019)
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Diego Chowell et al.
NATURE MEDICINE (2019)
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
S. Venkatesan et al.
ANNALS OF ONCOLOGY (2018)
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Josine Quispel-Janssen et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Strelka2: fast and accurate calling of germline and somatic variants
Sangtae Kim et al.
NATURE METHODS (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing
Deng Pan et al.
SCIENCE (2018)
CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial
Dean A. Fennell et al.
TRIALS (2018)
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory factors
Tao Wang et al.
CANCER DISCOVERY (2018)
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Ludmila Danilova et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Kyle Ellrott et al.
CELL SYSTEMS (2018)
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Vasiliki Panou et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Jutija Hmeljaki et al.
CANCER DISCOVERY (2018)
Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
Zsofia Sztupinszki et al.
NPJ BREAST CANCER (2018)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Evan W. Alley et al.
LANCET ONCOLOGY (2017)
Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
Chimed-Ochir Odgerel et al.
OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2017)
Fast and accurate HLA typing from short-read next-generation sequence data with xHLA
Chao Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan et al.
CELL (2017)
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano et al.
ONCOGENE (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
Raphael Bueno et al.
NATURE GENETICS (2016)
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Sachet A. Shukla et al.
NATURE BIOTECHNOLOGY (2015)
Personalized genomic analyses for cancer mutation discovery and interpretation
Sian Jones et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing
Noushin Niknafs et al.
PLOS COMPUTATIONAL BIOLOGY (2015)
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Francine Baumann et al.
CARCINOGENESIS (2015)
The IPD and IMGT/HLA database: allele variant databases
James Robinson et al.
NUCLEIC ACIDS RESEARCH (2015)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
L. M. Krug et al.
LUNG CANCER (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
An Integrated Tool to Study MHC Region: Accurate SNV Detection and HLA Genes Typing in Human MHC Region Using Targeted High-Throughput Sequencing
Hongzhi Cao et al.
PLOS ONE (2013)
Using synthetic templates to design an unbiased multiplex PCR assay
Christopher S. Carlson et al.
NATURE COMMUNICATIONS (2013)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Hiroki Ishikawa et al.
NATURE (2008)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
